bioRxivGeneticsPreprint
Genetic aberrations in chromatin factors are pervasive, mutually exclusive, associated with a high mutational burden and improved response to checkpoint immunotherapy in cancer
Martina MarkovskaiD, Rodney Alexander RosaliaiD, Aleksandra Stajkovska, Sanja Mehandziska, Marija Janevska, Ivan KungulovskiiD, Zan K. MitreviD, Goran KungulovskiiD
Abstract
In recent years, it has been shown that many of the pervasive genetic defects in cancer occur in chromatin modifiers. Herein, we analyzed the distribution and mutual relationships of genetic aberrations in relevant chromatin modifiers in tens of thousands of publicly available cancer datasets. We observed that in general, they are mutually exclusive, and their prevalence is higher in some types of cancers compared to others. Moreover, we observed a strong association between aberrations in selected chromatin modifiers and tumor mutational burden, leading to an improved response to checkpoint immunotherapy. All in all, this study uncovered interesting relationships between chromatin factors and features of cancer, which warrant follow up functional and clinical studies.
- organism: human
- assay: whole-genome sequencing
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy
Goran Kungulovski, Marija Gjorgjievska, … Zan Mitrev·medRxiv·Oct 15, 2024
- Genome-Wide Association Analysis Identifies Genetic Correlates of Immune Infiltrates in Solid Tumors.
N. O. Siemers, J. L. Holloway, … J. D. Szustakowski·bioRxiv·May 11, 2017
- Therapy-associated mutagenesis at CTCF binding sites is shaped by chromatin context and DNA repair capacity
Kevin C.L. Cheng, Zoe P. Klein, … Jüri Reimand·bioRxiv·Apr 18, 2026
- Disturbance of poised chromatin coincides with increased expression of developmental genes in cancer
Stephan H Bernhart, Helene Kretzmer, … Steve Hoffmann·bioRxiv·Mar 29, 2015
- CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance
Alex Watterson, Gabriele Picco, … Matthew A. Coelho·Cell Reports MedicinePeer-reviewed·Jan 1, 2026
- Immune Checkpoint Blockade Delays Cancer and Extends Survival in Murine DNA Polymerase Mutator Syndromes
Akshada Sawant, Fuqian Shi, … Eileen White·Cancer ResearchPeer-reviewed·Dec 30, 2024